skip to content
Detailed Quote
5i Report

Review of Knight Therapeutics

SEP 21, 2023 - The share price of GUD has declined over the years, while its fundamentals have been mixed. The company maintains a very strong balance sheet and has grown its top line nicely, but its profits have declined over the years leading to a questionable outlook. GUD has been a disappointment for many, us included. Due to some of its fundamentals maintaining their strength (balance sheet, revenue growth), we have kept it in our coverage list, however, we feel it has been held long enough and with declining margins, we are dropping coverage on Knight Therapeutics (GUD).

Download Report
Company Profile
{tplLang.businessdescription | toLang tLang}
{ profileData.description }

{tplLang.details | toLang tLang}

{tplLang.ceo | toLang tLang}
{profileData.profile.details.ceo}
{tplLang.employees | toLang tLang}
{profileData.profile.details.employees | numeraljs '0,0'}
{tplLang.issuetype | toLang tLang}
{profileData.profile.details.issuetype | asIssueType}

{tplLang.industryclassifications | toLang tLang}

{tplLang.sector | toLang tLang}
{profileData.profile.classification.sector}
{tplLang.industry | toLang tLang}
{profileData.profile.classification.industry}

{tplLang.toolname| toLang tLang}

There is no {tplLang.toolname| toLang tLang} currently available for {data.symbolstring}.
Interactive Chart
Key Ratios
Earnings
Analyst Recommendations
5i Recent Questions
Q: It was mentioned in the 31 March 2025 end quarterly report that the company is buying out some asset back from Endo for 100-mil plus inventory. Do you think that the asset which company purchased will do well as Endo acquired it and kept it. Now they are disposing it. Is company found them not valuable enough to generate good return? If that is the reason then why GUD bought it? Will GUD manage to generate good return out of it?
Thanks
Piyush
Read Answer Asked by Piyush on June 05, 2025
Insiders
Share Information
News and Media
Looking for more? Sign up for a FREE 14 day trial! No credit card required

We invite you to sign up for a 14 day free trial of 5i Research!
Experience all the benefits and tools we have to offer; stock research, model portfolios, Q&A with our experts, and so much more. Join a community of like-minded investors today!